Molecular Partners AG (XSWX:MOLN) Gross-Profit-to-Asset % : 5.70% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Molecular Partners AG's annualized Gross Profit for the quarter that ended in Mar. 2024 was CHF10.95 Mil. Molecular Partners AG's average Total Assets over the quarter that ended in Mar. 2024 was CHF191.98 Mil. Therefore, Molecular Partners AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 5.70%.

Molecular Partners AG Gross-Profit-to-Asset % Historical Data

The historical data trend for Molecular Partners AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Gross-Profit-to-Asset % Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

15.67

6.39

5.18

87.17

3.06

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															4.81	0.70	4.53	1.98	5.70

Competitive Comparison of Molecular Partners AG's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Molecular Partners AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Gross-Profit-to-Asset % falls into.

Molecular Partners AG Gross-Profit-to-Asset % Calculation

Molecular Partners AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	7.038	/	( (262.258	+	198.352)	/ 2 )
	=	7.038	/	230.305
	=	3.06 %

Molecular Partners AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	10.952	/	( (198.352	+	185.605)	/ 2 )
	=	10.952	/	191.9785
	=	5.70 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Molecular Partners AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.